In This Article:
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas
Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET
Key opinion leaders to participate in Avidity sponsored industry forum event "Advancing RNA Therapeutics", March 17, 2025, at 7:00 a.m. CT/8:00 a.m. ET
SAN DIEGO, March 12, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting one oral and two poster presentations at the 2025 MDA Clinical & Scientific Conference (MDA) in Dallas, Texas, being held March 16-19, 2025 and will host an investor and analyst webcast event on March 17, 2025.
2025 MDA Clinical & Scientific Conference Oral & Poster Presentations
March 19, 2025: 9:00 a.m. – 9:15 a.m. CT
-
Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation)
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, and EXPLORE44® trial investigator, will present topline del-zota data from Avidity's Phase 1/2 EXPLORE44 trial for people living with Duchenne Muscular Dystrophy amenable to exon 44 skipping (DMD44).
March 16-18, 2025: 6:00 p.m. – 8:00 p.m. CT
-
Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (poster presentation)
-
Phase 3, randomized, global study assessing efficacy and safety of del-desiran for the treatment of myotonic dystrophy type 1: HARBOR™ trial design (poster presentation)
The presentation and posters will be available on the publications page of Avidity's website at https://www.aviditybiosciences.com following the conference.
Avidity Sponsored Industry Forum Breakfast Event During MDA Conference
On March 17, 2025, 7:00 a.m. CT, Mike Flanagan, PhD, Chief Scientific Officer at Avidity, will host an industry forum breakfast titled "Advancing RNA Therapeutics: Exploring Antibody Oligonucleotide Conjugates (AOCs) for Rare Neuromuscular Diseases." Dr. Flanagan will be joined by guest speaker, Nicholas E. Johnson, MD, MSCI, FAAN, Vice Chair for Research, Department of Neurology, Virginia Commonwealth University, and will also be joined by Jeffrey M. Statland, MD, Professor of Neurology, University of Kansas Medical Center, and Johanna Hamel, MD, Associate Professor of Neurology, Psychology and Laboratory Medicine, University of Rochester to take part in a Q&A session. Participation will be open to all MDA Conference registered attendees.